Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2012: 107/5(May) pp. 803-1007
Pages: 838-847

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

M. V. Huisman (1), G. Y. H. Lip (2), H.-C. Diener (3), M. Brueckmann (4), J. van Ryn (5), A. Clemens (4)

(1) Departments of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands; (2) University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK; (3) Department of Neurology, University Hospital Essen, Essen, Germany; (4) Global Clinical Development and Medical Affairs, Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany; (5) Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany


Atrial fibrillation, bleeding, oral anticoagulant, dabigatran


Dabigatran etexilate is a new oral anticoagulant recently approved in Europe for the prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. With a fast onset of action and a predictable anticoagulant effect obviating the need for coagulation monitoring, dabigatran etexilate offers practical advantages over vitamin K antagonists in clinical practice. However, clinicians may have questions about practical aspects of dabigatran etexilate use including monitoring anticoagulant efficacy, interruption for surgical or invasive procedures and management of bleeding. This review article aims to address these concerns and provide guidance on the use of dabigatran etexilate in special situations, such as acute coronary syndromes and cardiac revascularisation. In addition, cut-off values for different coagulation assay results associated with an increased risk of bleeding are given.

You may also be interested in...

Results from the Dresden NOAC Registry

Online Supplementary Material

J. Beyer-Westendorf (1), F. Ebertz (1), K. Förster (1), V. Gelbricht (1), F. Michalski (1), C. Köhler (1), S. Werth (1), H. Endig (1), S. Pannach (2), L. Tittl (1), K. Sahin (3), K. Daschkow (1), N. Weiss (1)

Thromb Haemost 2015 113 6: 1247-1257

Meta-analysis of observational analyses

W. Darwiche (1), T. Bejan-Angoulvant (1), D. Angoulvant (1), D. Babuty (1), L. Fauchier (1)

Thromb Haemost 2016 : -

Meta-analysis of observational comparison studies with vitamin K antagonists

Online Supplementary Material

See also Freedman, Lip

J. Carmo (1), F. Moscoso Costa (2), J. Ferreira (1), M. Mendes (1)

Thromb Haemost 2016 116 4: 754-763